Search

Now showing items 1-10 of 20

Treating multiple sclerosis with generic cladribine

Alvarez-Gonzalez, C; Allen-Philbey, K; Mathews, J; Espasandin, M; Turner, BP; Gnanapavan, S; Marta, M; Giovannoni, G; Baker, D; Schmierer, K (2016)

Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine

Yildiz, O; Mao, Z; Adams, A; Dubuisson, N; Allen-Philbey, K; Giovannoni, G; Malaspina, A; Baker, D; Gnanapavan, S; Schmierer, K (2018-08)

TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE

Alvarez-Gonzalez, C; Allen-Philbey, K; Mathews, J; Turner, BP; Baker, D; Gnanapavan, S; Marta, M; Giovannoni, G; Schmiere, K (2016-12)

Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.

Mao, Z; Álvarez-González, C; Allen-Philbey, K; De Trane, S; Yildiz, O; Campion, T; Adams, A; Turner, BP; Marta, M; Gnanapavan, S;... (Elsevier/Science Direct, 2018-11-02)

BACKGROUND: Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with ...

Elevated neurofilament light chain levels in progressive multiple sclerosis effectively reduced by cladribine treatment

Yildiz, O; Mao, Z; Adams, A; Dubuisson, N; Allen-Philbey, K; Giovannoni, G; Malaspina, A; Baker, D; Gnanapavan, S; Schmierer, K (2018)

Cladribine personalised dosing in people with MS (n > 200) - four years experience in clinical care.

De Trane, S; Mao, Z; Alvarez-Gonzalez, C; Allen-Philbey, K; Yildiz, O; Campion, T; Adams, A; Turner, BP; Marta, M; Gnanapavan, S;... (2018-10)

Severe skin reactions associated with cladribine in people with multiple sclerosis

Mateo-Casas, M; Reyes, S; O'Toole, EA; De Trane, S; Yildiz, O; Allen-Philbey, K; Mathews, J; Baker, D; Giovannoni, G; Schmierer, K (2020-08)

Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study

Smets, I; Holden, D; Bianchi, L; Ammoscato, F; Allen-Philbey, K; Baker, D; Turner, B; Marta, M; Giovannoni, G; Macdougall, A;... (2022)

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.

Allen-Philbey, K; De Trane, S; MacDougall, A; Adams, A; Bianchi, L; Campion, T; Giovannoni, G; Gnanapavan, S; Holden, DW; Marta, M;... (2023)

BACKGROUND: Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges ...

CHARIOTMS - CLADRIBINE TO HALT DETERIORATION IN PEOPLE WITH ADVANCED MULTIPLE SCLEROSIS (PWAMS)

Schmierer, K; Baker, D; Nawaz, T; Allen-Philbey, K; Barkhof, F; Chataway, J; Hooper, R; Mihaylova, B; Hobart, J; Pavitt, S (2022)